Crawford’s revenue climbs to £18.3m

CHESHIRE-based advanced wound care business Crawford Healthcare is celebrating a 36% increase in global turnover to £18.3m.

The Knutsford group, which develops and sells wound care and dermatology products, reported a 31% revenue growth in the UK along with an increase in EBITDA UK profitability from 18% to 24%.

Crawford says the growth has been fuelled by Crawford’s increasing activity in the US, resulting from Crawford’s considerable investment in the region, where senior leadership have introduced a best in class sales and marketing operation.

As well as success in the US, the past six months have seen the development of a strategic partnership with European healthcare business OPED AG, which will introduce Crawford’s products in Germany, Europe’s largest advanced wound care market.

Crawford chief executive Richard Anderson said: “Domestic performance remains the bedrock of our group’s expansion and market data indicates that we are the fastest growing wound care business in the UK.

“Our goal is to replicate our UK successes in key overseas markets and, in particular, developing our US business remains an important strategic aim for the business.

 “Over the last few years, Crawford has transformed into a fully integrated healthcare business. Our R&D team has been responsible for delivering a pipeline of incrementally innovative and disruptive technologies that we’ve been able to bring to market swiftly through our in‑house manufacturing capabilities in the UK.

“We expect the outlook for 2016 to be one of continued growth in the underlying UK business along with making considerable progress in the US and Germany, supported by financial investment by the group. I’m pleased to report we are trading ahead of expectations so far in the new financial year.”